UCB (OTCMKTS:UCBJF) Shares Gap Down - Here's What Happened

Key Points

• UCB SA shares experienced a significant drop, opening at $235.05 after closing the previous day at $245.64, reflecting a gap down in trading.
• Despite the share price decline, Morgan Stanley has maintained an "overweight" rating for UCB, contributing to a consensus rating of "Buy" from analysts.
• The company has a debt-to-equity ratio of 0.33, indicating a relatively low level of debt compared to equity, alongside strong liquidity ratios with a quick ratio of 0.78.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $245.64, but opened at $235.05. UCB shares last traded at $235.05, with a volume of 516 shares.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reaffirmed an "overweight" rating on shares of UCB in a research note on Monday, September 8th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, UCB presently has a consensus rating of "Buy".

UCB Trading Down 4.3%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average price of $226.49 and a 200 day moving average price of $194.55.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.